vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and PHINIA INC. (PHIN). Click either name above to swap in a different company.
PHINIA INC. is the larger business by last-quarter revenue ($889.0M vs $346.4M, roughly 2.6× HAEMONETICS CORP). On growth, PHINIA INC. posted the faster year-over-year revenue change (6.7% vs 4.8%). HAEMONETICS CORP produced more free cash flow last quarter ($209.9M vs $67.0M). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (1.5% CAGR vs 1.5%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
PHINIA Inc. is a global automotive technology provider specializing in fuel injection systems, starters, alternators, and hybrid/electric vehicle components. It serves OEMs and aftermarket customers across North America, Europe, Asia Pacific and key markets, covering passenger car, commercial vehicle and industrial mobility segments.
HAE vs PHIN — Head-to-Head
Income Statement — Q4 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $346.4M | $889.0M |
| Net Profit | $97.3M | — |
| Gross Margin | 57.2% | 21.7% |
| Operating Margin | 36.1% | 7.8% |
| Net Margin | 28.1% | — |
| Revenue YoY | 4.8% | 6.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $1.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $346.4M | — | ||
| Q4 25 | $339.0M | $889.0M | ||
| Q3 25 | $327.3M | $908.0M | ||
| Q2 25 | $321.4M | $890.0M | ||
| Q1 25 | $330.6M | $796.0M | ||
| Q4 24 | $348.5M | $833.0M | ||
| Q3 24 | $345.5M | $839.0M | ||
| Q2 24 | $336.2M | $868.0M |
| Q1 26 | $97.3M | — | ||
| Q4 25 | $44.7M | — | ||
| Q3 25 | $38.7M | $13.0M | ||
| Q2 25 | $34.0M | $46.0M | ||
| Q1 25 | $58.0M | $26.0M | ||
| Q4 24 | $37.5M | — | ||
| Q3 24 | $33.8M | $31.0M | ||
| Q2 24 | $38.4M | $14.0M |
| Q1 26 | 57.2% | — | ||
| Q4 25 | 59.7% | 21.7% | ||
| Q3 25 | 59.5% | 22.0% | ||
| Q2 25 | 59.8% | 22.1% | ||
| Q1 25 | 58.4% | 21.6% | ||
| Q4 24 | 55.5% | 22.7% | ||
| Q3 24 | 54.2% | 22.3% | ||
| Q2 24 | 52.0% | 21.7% |
| Q1 26 | 36.1% | — | ||
| Q4 25 | 19.9% | 7.8% | ||
| Q3 25 | 17.9% | 3.7% | ||
| Q2 25 | 16.8% | 10.0% | ||
| Q1 25 | 21.6% | 7.8% | ||
| Q4 24 | 16.9% | 6.1% | ||
| Q3 24 | 15.0% | 7.9% | ||
| Q2 24 | 11.8% | 8.2% |
| Q1 26 | 28.1% | — | ||
| Q4 25 | 13.2% | — | ||
| Q3 25 | 11.8% | 1.4% | ||
| Q2 25 | 10.6% | 5.2% | ||
| Q1 25 | 17.5% | 3.3% | ||
| Q4 24 | 10.8% | — | ||
| Q3 24 | 9.8% | 3.7% | ||
| Q2 24 | 11.4% | 1.6% |
| Q1 26 | — | — | ||
| Q4 25 | $0.95 | $1.14 | ||
| Q3 25 | $0.81 | $0.33 | ||
| Q2 25 | $0.70 | $1.14 | ||
| Q1 25 | $1.17 | $0.63 | ||
| Q4 24 | $0.74 | $0.13 | ||
| Q3 24 | $0.66 | $0.70 | ||
| Q2 24 | $0.74 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $245.4M | $359.0M |
| Total DebtLower is stronger | $1.2B | $970.0M |
| Stockholders' EquityBook value | $796.3M | $1.6B |
| Total Assets | $2.4B | $3.8B |
| Debt / EquityLower = less leverage | 1.53× | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $245.4M | — | ||
| Q4 25 | $363.4M | $359.0M | ||
| Q3 25 | $296.4M | $349.0M | ||
| Q2 25 | $292.9M | $347.0M | ||
| Q1 25 | $306.8M | $373.0M | ||
| Q4 24 | $320.8M | $484.0M | ||
| Q3 24 | $299.3M | $477.0M | ||
| Q2 24 | $344.4M | $339.0M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $970.0M | ||
| Q3 25 | $1.2B | $990.0M | ||
| Q2 25 | $1.2B | $990.0M | ||
| Q1 25 | $1.2B | $989.0M | ||
| Q4 24 | — | $988.0M | ||
| Q3 24 | — | $987.0M | ||
| Q2 24 | — | $821.0M |
| Q1 26 | $796.3M | — | ||
| Q4 25 | $911.5M | $1.6B | ||
| Q3 25 | $849.2M | $1.6B | ||
| Q2 25 | $882.3M | $1.6B | ||
| Q1 25 | $820.8M | $1.5B | ||
| Q4 24 | $906.9M | $1.6B | ||
| Q3 24 | $878.9M | $1.7B | ||
| Q2 24 | $905.4M | $1.7B |
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.5B | $3.8B | ||
| Q3 25 | $2.4B | $4.0B | ||
| Q2 25 | $2.5B | $3.9B | ||
| Q1 25 | $2.5B | $3.7B | ||
| Q4 24 | $2.5B | $3.8B | ||
| Q3 24 | $2.5B | $4.0B | ||
| Q2 24 | $2.5B | $3.9B |
| Q1 26 | 1.53× | — | ||
| Q4 25 | 1.34× | 0.61× | ||
| Q3 25 | 1.44× | 0.62× | ||
| Q2 25 | 1.39× | 0.61× | ||
| Q1 25 | 1.49× | 0.64× | ||
| Q4 24 | — | 0.63× | ||
| Q3 24 | — | 0.58× | ||
| Q2 24 | — | 0.47× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $293.2M | $96.0M |
| Free Cash FlowOCF − Capex | $209.9M | $67.0M |
| FCF MarginFCF / Revenue | 60.6% | 7.5% |
| Capex IntensityCapex / Revenue | 9.5% | 3.3% |
| Cash ConversionOCF / Net Profit | 3.01× | — |
| TTM Free Cash FlowTrailing 4 quarters | $417.1M | $188.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $293.2M | — | ||
| Q4 25 | $93.6M | $96.0M | ||
| Q3 25 | $111.3M | $119.0M | ||
| Q2 25 | $17.4M | $57.0M | ||
| Q1 25 | $116.6M | $40.0M | ||
| Q4 24 | $43.8M | $73.0M | ||
| Q3 24 | $48.8M | $95.0M | ||
| Q2 24 | $-27.4M | $109.0M |
| Q1 26 | $209.9M | — | ||
| Q4 25 | $87.2M | $67.0M | ||
| Q3 25 | $106.3M | $93.0M | ||
| Q2 25 | $13.6M | $23.0M | ||
| Q1 25 | $100.9M | $5.0M | ||
| Q4 24 | $35.2M | $53.0M | ||
| Q3 24 | $39.4M | $70.0M | ||
| Q2 24 | $-33.1M | $92.0M |
| Q1 26 | 60.6% | — | ||
| Q4 25 | 25.7% | 7.5% | ||
| Q3 25 | 32.5% | 10.2% | ||
| Q2 25 | 4.2% | 2.6% | ||
| Q1 25 | 30.5% | 0.6% | ||
| Q4 24 | 10.1% | 6.4% | ||
| Q3 24 | 11.4% | 8.3% | ||
| Q2 24 | -9.8% | 10.6% |
| Q1 26 | 9.5% | — | ||
| Q4 25 | 1.9% | 3.3% | ||
| Q3 25 | 1.5% | 2.9% | ||
| Q2 25 | 1.2% | 3.8% | ||
| Q1 25 | 4.7% | 4.4% | ||
| Q4 24 | 2.5% | 2.4% | ||
| Q3 24 | 2.7% | 3.0% | ||
| Q2 24 | 1.7% | 2.0% |
| Q1 26 | 3.01× | — | ||
| Q4 25 | 2.09× | — | ||
| Q3 25 | 2.88× | 9.15× | ||
| Q2 25 | 0.51× | 1.24× | ||
| Q1 25 | 2.01× | 1.54× | ||
| Q4 24 | 1.17× | — | ||
| Q3 24 | 1.44× | 3.06× | ||
| Q2 24 | -0.71× | 7.79× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
PHIN
| Customer | $618.0M | 70% |
| Fuel Systems | $194.0M | 22% |
| Other | $77.0M | 9% |
